|Articles|June 1, 2008

Pharmaceutical Executive

  • Pharmaceutical Executive-06-01-2008
  • Volume 0
  • Issue 0

Nancy Phelan, Wyeth

S

Nancy Phelan

ED, Consumer Communications and E-marketing, Wyeth

MOST RECENT HIT: Launched birth control pill Lybrel

ADDED VALUE: "Best Practices" brainiac

I saw firsthand the impact that disease can have on the person who has the disease, but also on the family," says Nancy Phelan. Her sister was often hospitalized with seer asthma, and not until Theo-Dur hit the market could she live a "normal" life. When it came to a career choice, Phelan chose pharma—Schering-Plough, the maker of Theo-Dur. After her field service, she rose fast into management, helping to take the allergy med Claritin over the counter. Winging it to Wyeth, she now helps with marketing strategy and best practices for all pharmaceutical brands. Phelan has a reputation for taking ethics as seriously as sales—a distinction for which she credits her industry mentors. "If you compromise once, you're going to compromise again," she says. As for her generation of new leaders, she says, "There does seem to be a new openness to new solutions, and an optimism that we can actually lead the change in healthcare, rather than only reacting once that happens."

Nancy Phelan

Articles in this issue

over 18 years ago

Mary Szela, Abbott

over 18 years ago

Mightier Than the Sword

over 18 years ago

Eric Floyd, Cephalon

over 18 years ago

Tightening the Chain

over 18 years ago

Kurt Graves, Vertex

over 18 years ago

Wendy Niebler, Shire

over 18 years ago

Perfectly Imperfect

over 18 years ago

Relaunching Reform

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.